WINNIPEG, MB,
March 23, 2022 /CNW/ -
Medicure Inc. ("Medicure" or the "Company") (TSXV:
MPH) (OTC: MCUJF), a company focused on the development and
commercialization of pharmaceuticals and healthcare products for
patients and prescribers in the United
States market, today reported that Chief Financial Officer
David Gurvey (CPA, CMA, B.Sc.) is
resigning, effective March 25,
2022.
Albert D. Friesen, PhD, CEO and
Chair of the Board of Directors, stated, "On behalf of everyone at
Medicure and our Board of Directors, we thank David for his
contributions to our Company and we wish him well in his future
endeavors."
The Company has initiated a search for a new Chief Financial
Officer with the capabilities and qualifications to accelerate
Medicure's growth and business strategy. Dr. Neil Owens, Chief Operating Officer of the
Company, will assume the role of interim Chief Financial Officer
upon Mr. Gurvey's resignation.
About Medicure Inc.
Medicure is a pharmaceutical
company focused on the development and commercialization of
innovative and affordable therapeutics for the U.S. market.
Medicure's sales force markets to physicians and other healthcare
professionals and now with E-Commerce integration, will be offering
patients and providers direct online ordering and home delivery.
Our vision is to become a leading pharmaceutical company within the
U.S, offering a growing portfolio of products that improve
patients' lives. The present focus of the Company is the marketing
and distribution of AGGRASTAT® (tirofiban hydrochloride) injection
and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through
the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also
operates Marley Drug®, Inc. ("Marley Drug"), a pharmacy located in
North Carolina that offers an
Extended Supply drug program serving all 50 states, Washington D.C. and most territories,
including Puerto Rico. Marley Drug
is committed to improving the health status of its patients and the
communities they serve while reducing overall health care costs for
employers and other health care consumers. For more information
visit www.marleydrug.com. To learn more about The Extended Supply
Generic Drug Program call 800.286.6781 or e-mail
info@marleydrug.com. For more information on Medicure please visit
https://www.medicure.com/. For additional information about
AGGRASTAT®, refer to the full Prescribing Information. For
additional information about ZYPITAMAG®, refer to the full
Prescribing Information.
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements contained in this
press release that are not statements of historical fact,
including, without limitation, statements containing the words
"believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of
applicable Canadian and U.S. federal securities laws (such
forward-looking information and forward-looking statements are
hereinafter collectively referred to as "forward-looking
statements"). Forward-looking statements, include estimates,
analysis and opinions of management of the Company made in light of
its experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's future product revenues, expected
results, including future revenue from P5P, the likelihood of
receiving a PRV, expected future growth in revenues, stage of
development, additional capital requirements, risks associated with
the completion and timing of clinical trials and obtaining
regulatory approval to market the Company's products, the ability
to protect its intellectual property, dependence upon collaborative
partners, changes in government regulation or regulatory approval
processes, and rapid technological change in the industry. Such
statements are based on a number of assumptions which may prove to
be incorrect, including, but not limited to, assumptions about:
general business and economic conditions; the impact of changes in
Canadian-US dollar and other foreign exchange rates on the
Company's revenues, costs and results; the timing of the receipt of
regulatory and governmental approvals for the Company's research
and development projects; the availability of financing for the
Company's commercial operations and/or research and development
projects, or the availability of financing on reasonable terms;
results of current and future clinical trials; the uncertainties
associated with the acceptance and demand for new products and
market competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended December 31, 2020.
View original
content:https://www.prnewswire.com/news-releases/medicure-announces-resignation-of-chief-financial-officer-and-succession-plan-301509407.html
SOURCE Medicure Inc.